IDO1 and non-small cell lung carcinoma: Because we had performed targeted MS measurements for PD-L1 and IDO1 in all 26 samples, we asked how global proteotypes intrinsically differed in immune checkpoint inhibitor naïve NSCLC as a function of expression of these two drug targets.